Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Non-steroidal anti-inflammatory drug Stories

2010-11-09 11:35:16

For patients at high risk of GI bleeding who require antiplatelet therapy for heart disease, the balance of risk and benefit favor concomitant use of acid suppressing drugs Using proton pump inhibitors (PPIs) and antiplatelet drugs (thienopyridines) together is an appropriate way of treating patients with cardiovascular (CV) disease who are at high risk of upper gastrointestinal (GI) bleeds, despite recent concerns about an adverse interaction between these two types of drugs, according to an...

2010-10-06 08:00:00

SEOUL, South Korea, Oct. 6 /PRNewswire/ -- CrystalGenomics, Inc. (www.cgxinc.com), a biopharmaceutical company with drug discovery and development capabilities, has just announced its plan to jointly conduct an investigational preclinical research project with The University of Texas MD Anderson Cancer Center. The purpose of this research is to explore the potential anti-tumor effects of CG100649, CrystalGenomics' clinical stage novel NSAID candidate, which is being developed as an...

2010-09-30 17:14:58

But for small number, joints got worse and drug development was put on hold A phase II clinical trial of the first new type of drug for musculoskeletal pain since aspirin shows that it significantly reduces knee pain in osteoarthritis, the most common osteoarthritis pain, according to new research from Northwestern Medicine. However, phase III trials of that drug, tanezumab, have been placed on clinical hold after 16 out of several thousand participants in the new trial developed...

2010-09-23 12:28:00

NASHVILLE, Tenn., Sept. 23 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced that Caldolor® (ibuprofen) Injection is gaining momentum and being approved for use in a growing number of medical facilities across the country. Several key U.S. hospitals, including Orlando Regional Medical Center, St. Elizabeth Healthcare in the Greater Cincinnati region and the Joseph M. Still Burn Centers, have added the product to their formularies for patient...

2010-09-14 01:13:35

A research team from the University of California, Davis and Peking University, China, has discovered a novel mechanism as to why the long-term, high-dosage use of the well-known arthritis pain medication, Vioxx, led to heart attacks and strokes. Their groundbreaking research may pave the way for a safer drug for millions of arthritis patients who suffer acute and chronic pain. Using metabolomic profiling to analyze murine (rodent) plasma, the scientists discovered that Vioxx causes a...

2010-08-30 12:14:00

NASHVILLE, Tenn., Aug. 30 /PRNewswire-FirstCall/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced the publication of new data supporting the safety and efficacy of Caldolor® (ibuprofen) Injection in pre and post-operative orthopedic surgery patients. The study, which was published in the August edition of the peer-reviewed journal Pain Medicine, concludes that IV ibuprofen significantly decreased pain and morphine use when compared with placebo. In the...

2010-06-09 05:55:00

TARRYTOWN, N.Y., June 9 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that a Phase 3 study in gout patients initiating allopurinol therapy to lower their uric acid levels showed that ARCALYST (rilonacept), also known as IL-1 Trap, prevented gout attacks, as measured by the primary endpoint of the number of gout flares per patient over the 16 week treatment period. Primary Endpoint: Patients who received ARCALYST at a weekly,...

2010-01-05 14:32:00

People with the heritable disorder of the skin called Gorlin syndrome who are genetically predisposed to develop basal cell carcinoma of the skin may have a new chemoprevention therapy on the horizon. According to results of a placebo-controlled, randomized, double-blind, Phase II study, the use of celecoxib was effective in inhibiting the development of basal cell carcinomas in a relatively rare group of patients who are highly susceptible to carcinoma. These findings are published in the...

2009-12-08 14:37:28

Press release from PLoS Medicine Cost-effectiveness studies are widely used to guide prescribing policy in many countries, as part of health technology assessment programs. However, a new study published this week in PLoS Medicine by Tjeerd-Pieter van Staa and colleagues suggests that cost-effectiveness analyses based on data from randomized controlled trials may not be realistic enough to accurately inform policy. In the study the researchers (affiliated with the General Practice Research...

2009-11-23 16:34:15

Provides lessons for post-market pharmaceutical safety Evidence of cardiovascular risks associated with taking Vioxx, the popular, nonsteroidal anti-inflammatory drug (rofecoxib), could have been identified nearly four years before its manufacturer, Merck & Co. Inc., voluntarily pulled the drug from the market. Led by Joseph Ross, MD, MHS, Assistant Professor of Geriatrics and Palliative Medicine and of Medicine at Mount Sinai School of Medicine, a team of six investigators analyzed 30...